-
公开(公告)号：US20180028552A1
公开(公告)日：2018-02-01
申请号：US15547427
申请日：2016-02-01
Applicant: Epizyme, Inc. , Celgene Corporation
Inventor： Christine Klaus , Maria Alejandra Raimondi , Scott Richard Daigle , Roy MacFarlane Pollock , Vivek Chopra
IPC: A61K31/7076 , A61K31/706
CPC classification number: A61K31/7076 , A61K31/706 , A61K31/7068 , A61K2300/00
Abstract: The present disclosure relates to a combination of an inhibitor of human histone methyltransferase DOT1L, such as EPZ-5676 or salts thereof, and one or more DNMT inhibitors, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
-
公开(公告)号：US10525074B2
公开(公告)日：2020-01-07
申请号：US15248080
申请日：2016-08-26
Applicant: Epizyme, Inc.
Inventor： Christine Klaus , Maria Alejandra Raimondi , Scott R. Daigle , Roy MacFarlane Pollock
IPC: A61K31/7076 , A61K31/704 , A61K31/706 , A61K31/7068 , A61K31/4745 , A61K31/135 , A61K31/5377 , A61K31/136 , A61K31/635
Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
-
公开(公告)号：US09446064B2
公开(公告)日：2016-09-20
申请号：US14210511
申请日：2014-03-14
Applicant: Epizyme, Inc.
Inventor： Christine Klaus , Maria Alejandra Raimondi , Scott R. Daigle , Roy MacFarlane Pollock
IPC: A61K31/7076 , A61K31/704 , A61K31/706 , A61K31/136 , A61K31/4745 , A61K31/7068 , A61K31/135 , A61K31/5377
CPC classification number: A61K31/7076 , A61K31/135 , A61K31/136 , A61K31/4745 , A61K31/5377 , A61K31/635 , A61K31/704 , A61K31/706 , A61K31/7068
Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
Abstract translation: 本发明涉及包含人组蛋白甲基转移酶DOT1L的抑制剂和一种或多种治疗剂，特别是抗癌剂的组合物，以及用于给予需要其治疗癌症的受试者的组合疗法的方法。
-
Patent Agency Ranking
公开(公告)号：US20170232030A1
公开(公告)日：2017-08-17
申请号：US15503542
申请日：2015-08-12
Applicant: Epizyme, Inc. , Celgene Corporation
Inventor： Christine Klaus , Maria Alejandra Raimondi , Scott Richard Daigle , Roy MacFarlane Pollock , Vivek Chopra
IPC: A61K31/7064 , A61K31/7068 , A61K31/519 , A61K45/06 , A61K31/706
CPC classification number: A61K31/7064 , A61K31/135 , A61K31/136 , A61K31/4045 , A61K31/4745 , A61K31/519 , A61K31/5377 , A61K31/704 , A61K31/706 , A61K31/7068 , A61K31/7076 , A61K45/06 , A61P35/00 , A61K2300/00
Abstract: The disclosure relates to combinations comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
-
公开(公告)号：US20170080010A1
公开(公告)日：2017-03-23
申请号：US15248080
申请日：2016-08-26
Applicant: Epizyme, Inc.
Inventor： Christine Klaus , Maria Alejandra Raimondi , Scott R. Daigle , Roy MacFarlane Pollock
IPC: A61K31/7076 , A61K31/706 , A61K31/635 , A61K31/4745 , A61K31/7068 , A61K31/135 , A61K31/704 , A61K31/136
Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
-
公开(公告)号：US20190083521A1
公开(公告)日：2019-03-21
申请号：US15512527
申请日：2015-08-12
Applicant: Epizyme, Inc.
Inventor： Christine Klaus , Maria Alejandra Raimondi , Scott Richard Daigle , Roy MacFarlane Pollock
IPC: A61K31/7076 , A61K31/7068 , A61K31/704 , A61K31/706 , A61K31/519 , A61K45/06 , A61P35/02 , A61K31/136 , A61K31/135 , A61K31/635 , A61K31/5377
Abstract: The disclosure relates to combinations comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
-
公开(公告)号：US20160045531A1
公开(公告)日：2016-02-18
申请号：US14776669
申请日：2014-03-14
Applicant: EPIZYME, INC.
Inventor： Christine Klaus , Maria Alejandra Raimondi , Scott Richard Daigle , Roy MacFarlane Pollock
IPC: A61K31/7076 , C07H19/044 , A61K31/7064 , A61K31/551 , A61K31/704 , A61K31/706 , A61K31/136 , A61K31/4745 , C07H19/16 , A61K31/7068
CPC classification number: A61K31/7076 , A61K31/136 , A61K31/4745 , A61K31/551 , A61K31/704 , A61K31/706 , A61K31/7064 , A61K31/7068 , C07H19/044 , C07H19/16 , A61K2300/00
Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
Abstract translation: 本发明涉及包含人组蛋白甲基转移酶DOT1L的抑制剂和一种或多种治疗剂，特别是抗癌剂的组合物，以及用于给予需要其治疗癌症的受试者的组合疗法的方法。
-
公开(公告)号：US20140323421A1
公开(公告)日：2014-10-30
申请号：US14210511
申请日：2014-03-14
Applicant: Epizyme, Inc.
Inventor： Christine Klaus , Maria Alejandra Raimondi , Scott R. Daigle , Roy MacFarlane Pollock
IPC: A61K31/7076 , A61K31/706 , A61K31/5377 , A61K31/4745 , A61K31/7068 , A61K31/135 , A61K31/704 , A61K31/136
CPC classification number: A61K31/7076 , A61K31/135 , A61K31/136 , A61K31/4745 , A61K31/5377 , A61K31/635 , A61K31/704 , A61K31/706 , A61K31/7068
Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
Abstract translation: 本发明涉及包含人组蛋白甲基转移酶DOT1L的抑制剂和一种或多种治疗剂，特别是抗癌剂的组合物，以及用于给予需要其治疗癌症的受试者的组合疗法的方法。
-
-
-
-
-
-
-
Search Results
8
records
(took 0.02 seconds)
